This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: eBC Panel Discussion on Key Studies - KEYNOTE-522, I-SPY 2.2, and NATALEE

570 views
October 4, 2024

Chapters

ESMO 2024 Highlights & Early Stage Discussion

00:00

KEYNOTE-522: Pembrolizumab in Triple Negative BC

00:47

I-SPY 2.2: Tailoring Neoadjuvant Treatment

10:13

Ribociclib Insights: NATALEE Updates, Eligibility, Age-Based Outcomes, Adjuvant treatment selection

21:55

Comments 0
Login to view comments. Click here to Login